| Schedule of segment reportable segments |
By Business Unit | | Provision for genomic screening services | | | Trading of industrial chemicals | | | Investment holding | | | Total | | | | Nine-month periods ended September 30, 2026 | | | | | | | | | | | | | | | REVENUE | | $ | 1,961 | | | $ | 144,954 | | | $ | - | | | $ | 146,915 | | | | | | | | | | | | | | | | | | | COST OF REVENUE | | | (1,250 | ) | | | (128,985 | ) | | | - | | | | (130,235 | ) | | | | | | | | | | | | | | | | | | GROSS PROFIT | | | 711 | | | | 15,969 | | | | - | | | | 16,680 | | | | | | | | | | | | | | | | | | | OTHER INCOME | | | | | | | | | | | | | | | | | Interest income | | | 38,273 | | | | 16,630 | | | | - | | | | 54,903 | | Gain from foreign exchange | | | 8,227 | | | | 1,790 | | | | 48 | | | | 10,065 | | Others | | | - | | | | 22,779 | | | | - | | | | 22,779 | | TOTAL OTHER INCOME | | | 46,500 | | | | 41,199 | | | | 48 | | | | 87,747 | | | | | | | | | | | | | | | | | | | OPERATING EXPENSES | | | | | | | | | | | | | | | | | Sales and marketing | | | (98,154 | ) | | | (2,790 | ) | | | (22,818 | ) | | | (123,762 | ) | Research and development | | | (41,736 | ) | | | - | | | | - | | | | (41,736 | ) | General and administrative | | | (180,877 | ) | | | (162,031 | ) | | | (600,034 | ) | | | (942,942 | ) | Provision for credit losses, net | | | - | | | | (76,814 | ) | | | - | | | | (76,814 | ) | Share-based compensation | | | - | | | | - | | | | (799,998 | ) | | | (799,998 | ) | TOTAL OPERATING EXPENSES | | | (320,767 | ) | | | (241,635 | ) | | | (1,422,850 | ) | | | (1,985,252 | ) | | | | | | | | | | | | | | | | | | LOSS FROM OPERATIONS | | | (273,556 | ) | | | (184,467 | ) | | | (1,422,802 | ) | | | (1,880,825 | ) | | | | | | | | | | | | | | | | | | FINANCE COSTS | | | - | | | | (1,574 | ) | | | (2,007 | ) | | | (3,581 | ) | | | | | | | | | | | | | | | | | | LOSS BEFORE TAX | | | (273,556 | ) | | | (186,041 | ) | | | (1,424,809 | ) | | | (1,884,406 | ) | | | | | | | | | | | | | | | | | | Tax expense | | | - | | | | - | | | | - | | | | - | | | | | | | | | | | | | | | | | | | NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | | $ | (273,556 | ) | | $ | (186,041 | ) | | $ | (1,424,809 | ) | | $ | (1,884,406 | ) |
| | Provision for | | | | | | | | | | | | | genomic | | | Trading of | | | | | | | | | | screening | | | industrial | | | Investment | | | | | | | services | | | chemicals | | | holding | | | Total | | | | Nine months period ended September 30, 2025 | | | | | | | | | | | | | | | REVENUE | | $ | 11,302 | | | $ | 6,929,849 | | | $ | - | | | $ | 6,941,151 | | | | | | | | | | | | | | | | | | | COST OF REVENUE | | | (4,995 | ) | | | (5,846,956 | ) | | | - | | | | (5,851,951 | ) | | | | | | | | | | | | | | | | | | GROSS PROFIT | | | 6,307 | | | | 1,082,893 | | | | - | | | | 1,089,200 | | | | | | | | | | | | | | | | | | | OTHER INCOME | | | | | | | | | | | | | | | | | Dividend income | | | - | | | | 21,752 | | | | - | | | | 21,752 | | Interest income | | | 63,646 | | | | 10,468 | | | | - | | | | 74,114 | | Fair value gain on investments in equity securities | | | - | | | | 28,256 | | | | - | | | | 28,256 | | Gain on disposal of investments in equity securities | | | - | | | | 42,376 | | | | - | | | | 42,376 | | Others | | | 10,919 | | | | 136,312 | | | | - | | | | 147,231 | | | | | | | | | | | | | | | | | | | TOTAL OTHER INCOME | | | 74,565 | | | | 239,164 | | | | - | | | | 313,729 | | | | | | | | | | | | | | | | | | | OPERATING EXPENSES | | | | | | | | | | | | | | | | | Sales and marketing | | | (86,275 | ) | | | (1,577,214 | ) | | | (37,202 | ) | | | (1,700,691 | ) | Research and development | | | (39,572 | ) | | | - | | | | - | | | | (39,572 | ) | General and administrative | | | (270,725 | ) | | | (492,464 | ) | | | (600,888 | ) | | | (1,364,077 | ) | Fair value loss on investments in equity securities | | | - | | | | (119,499 | ) | | | - | | | | (119,499 | ) | Provision for credit losses, net | | | - | | | | (121,030 | ) | | | - | | | | (121,030 | ) | | | | | | | | | | | | | | | | | | TOTAL OPERATING EXPENSES | | | (396,572 | ) | | | (2,310,207 | ) | | | (638,090 | ) | | | (3,344,869 | ) | | | | | | | | | | | | | | | | | | LOSS FROM OPERATIONS | | | (315,700 | ) | | | (988,150 | ) | | | (638,090 | ) | | | (1,941,940 | ) | | | | | | | | | | | | | | | | | | FINANCE COSTS | | | (32 | ) | | | (6,266 | ) | | | (252 | ) | | | (6,550 | ) | | | | | | | | | | | | | | | | | | LOSS BEFORE TAX | | | (315,732 | ) | | | (994,416 | ) | | | (638,342 | ) | | | (1,948,490 | ) | | | | | | | | | | | | | | | | | | Tax expense | | | - | | | | - | | | | - | | | | - | | | | | | | | | | | | | | | | | | | NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | | $ | (315,732 | ) | | $ | (994,416 | ) | | $ | (638,342 | ) | | $ | (1,948,490 | ) |
By Country | | Malaysia | | | United States | | | Total | | | | Nine-month period ended September 30, 2026 | | | | | | | | | | | | REVENUE | | $ | 146,915 | | | $ | - | | | $ | 146,915 | | | | | | | | | | | | | | | COST OF REVENUE | | | (130,235 | ) | | | - | | | | (130,235 | ) | | | | | | | | | | | | | | GROSS PROFIT | | | 16,680 | | | | - | | | | 16,680 | | | | | | | | | | | | | | | OTHER INCOME | | | | | | | | | | | | | Interest income | | | 54,903 | | | | - | | | | 54,903 | | Gain from foreign exchange | | | 10,017 | | | | 48 | | | | 10,065 | | Others | | | 22,779 | | | | - | | | | 22,779 | | TOTAL OTHER INCOME | | | 87,699 | | | | 48 | | | | 87,747 | | | | | | | | | | | | | | | OPERATING EXPENSES | | | | | | | | | | | | | Sales and marketing | | | (100,944 | ) | | | (22,818 | ) | | | (123,762 | ) | Research and development | | | (41,736 | ) | | | - | | | | (41,736 | ) | General and administrative | | | (342,908 | ) | | | (600,034 | ) | | | (942,942 | ) | Provision for credit losses, net | | | (76,814 | ) | | | - | | | | (76,814 | ) | Share-based compensation | | | - | | | | (799,998 | ) | | | (799,998 | ) | TOTAL OPERATING EXPENSES | | | (562,402 | ) | | | (1,422,850 | ) | | | (1,985,252 | ) | | | | | | | | | | | | | | LOSS FROM OPERATIONS | | | (458,023 | ) | | | (1,422,802 | ) | | | (1,880,825 | ) | | | | | | | | | | | | | | FINANCE COSTS | | | (1,574 | ) | | | (2,007 | ) | | | (3,581 | ) | | | | | | | | | | | | | | LOSS BEFORE TAX | | | (459,597 | ) | | | (1,424,809 | ) | | | (1,884,406 | ) | | | | | | | | | | | | | | Tax expense | | | - | | | | - | | | | - | | | | | | | | | | | | NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | | $ | (459,597 | ) | | $ | (1,424,809 | ) | | $ | (1,884,406 | ) |
By Country | | Malaysia | | | United States | | | Total | | | | Nine-month period ended September 30, 2025 | | | | | | | | | | | | REVENUE | | $ | 6,941,151 | | | $ | - | | | $ | 6,941,151 | | | | | | | | | | | | | | | COST OF REVENUE | | | (5,851,951 | ) | | | - | | | | (5,851,951 | ) | | | | | | | | | | | | | | GROSS PROFIT | | | 1,089,200 | | | | - | | | | 1,089,200 | | | | | | | | | | | | | | | OTHER INCOME | | | | | | | | | | | | | Dividend income | | | 21,752 | | | | - | | | | 21,752 | | Interest income | | | 74,114 | | | | - | | | | 74,114 | | Fair value gain on investments in equity securities | | | 28,256 | | | | - | | | | 28,256 | | Gain on disposal of investments in equity securities | | | 42,376 | | | | - | | | | 42,376 | | Others | | | 147,231 | | | | | | | | 147,231 | | TOTAL OTHER INCOME | | | 313,729 | | | | - | | | | 313,729 | | | | | | | | | | | | | | | OPERATING EXPENSES | | | | | | | | | | | | | Sales and marketing | | | (1,663,489 | ) | | | (37,202 | ) | | | (1,700,691 | ) | Research and development | | | (39,572 | ) | | | - | | | | (39,572 | ) | General and administrative | | | (763,189 | ) | | | (600,888 | ) | | | (1,364,077 | ) | Fair value loss on investments in equity securities | | | (119,499 | ) | | | - | | | | (119,499 | ) | Provision for credit losses, net | | | (121,030 | ) | | | - | | | | (121,030 | ) | TOTAL OPERATING EXPENSES | | | (2,706,779 | ) | | | (638,090 | ) | | | (3,344,869 | ) | | | | | | | | | | | | | | LOSS FROM OPERATIONS | | | (1,303,850 | ) | | | (638,090 | ) | | | (1,941,940 | ) | | | | | | | | | | | | | | FINANCE COSTS | | | (6,298 | ) | | | (252 | ) | | | (6,550 | ) | | | | | | | | | | | | | | LOSS BEFORE TAX | | | (1,310,148 | ) | | | (638,342 | ) | | | (1,948,490 | ) | | | | | | | | | | | | | | Tax expense | | | - | | | | - | | | | - | | | | | | | | | | | | | | | NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | | $ | (1,310,148 | ) | | $ | (638,342 | ) | | $ | (1,948,490 | ) |
| | Provision for genomic screening services | | | Trading of industrial chemicals | | | Investment holding | | | Total | | | | As of September 30, 2026 | | | | | | | | | | | | | | | Segment assets | | $ | 1,643,808 | | | $ | 4,250,922 | | | $ | 2,865,971 | | | $ | 8,760,701 | | | | | | | | | | | | | | | | | | | Included in the measure of segment assets are: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Addition to non-current assets other than financial instruments and deferred tax assets | | | 163 | | | | 78,323 | | | | - | | | | 78,486 | |
| | Provision for genomic screening services | | | Trading of industrial chemicals | | | Investment holding | | | Total | | | | As of December 31, 2025 | | | | | | | | | | | | | | | Segment assets | | $ | 2,281,947 | | | $ | 4,577,690 | | | $ | 2,393,147 | | | $ | 9,252,784 | | | | | | | | | | | | | | | | | | | Included in the measure of segment assets are: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Addition to non-current assets other than financial instruments and deferred tax assets | | | 1,382 | | | | 35,589 | | | | - | | | | 36,971 | |
|